On September 5, 2023 NUCLIDIUM reported the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023 (Press release, NUCLIDIUM, SEP 5, 2023, View Source [SID1234634903]). The full pre-clinical data packages demonstrate the company’s progress in the selection of diagnostic lead candidates for the KaliosTM and NuriProTM programs, as well as the successful establishment of a clinical-scale production process for the diagnostic component of its TraceNETTM program. The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation. The programs are part of NUCLIDIUM’s comprehensive pipeline of copper-based radiotheranostics based on its flexible CuTraceTM platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"More than 50% of cancer patients are misdiagnosed which significantly impacts their survival chances. We aim to address this challenge with our theranostic approach leveraging the advantageous properties of copper isotopes to reduce side effects and increase the precision and efficacy of radiopharmaceuticals. The positive pre-clinical data for the diagnostic candidates from three of our programs and the preparation for clinical translation represent an important step for NUCLIDIUM. Our rapid progress towards clinical evaluation will help us establish a new standard in precision oncology and offer patients better access to highly effective and safe diagnostics and treatment options," said Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM.
Presentation Information:
Oral presentation on the development of diagnostic candidates from the KaliosTM program targeting Fibroblast Activation Protein (FAP)-expressing tumours such as breast and lung cancer
Title: Enhancing the tumor-to-background ratio of FAP-positive PET/CT scans with the novel 61Cu-Kalios derivatives: synthesis, in vitro and in vivo characterization
Session: New Roads Towards FAP-directed Theranostics
Presenter: Jacopo Millul, PhD, Postdoctoral Scientist at University Hospital Basel
Date & Time: September 11th, 3 pm CEST
Summary:
The presentation will detail the development and characterization of a 61Cu-based diagnostic to more efficiently visualize epithelial tumours. These types of tumours make up the majority of all cancer cases and often overexpress Fibroblast Activation Protein (FAP), making FAP a promising target for cancer diagnostics and therapies. The data demonstrate the successful synthesis of four new FAP-targeting ligands with high hydrophilicity and affinity against FAP that were conjugated with 61Cu via the NODAGA chelator. In vivo analyses showed that two of the diagnostic KaliosTM conjugates are particularly promising for delayed time-point imaging, with superior tumour-to-background ratios at 4 hours. To select the best candidate for clinical translation, these two diagnostic KaliosTM conjugates will be directly compared to a 68Ga-based standard FAP-radiodiagnostic.
Oral presentation on NUCLIDIUM’s successfully established 61Cu production and on the labelling method for the diagnostic lead candidate from the TraceNETTM program targeting somatostatin-receptor-expressing neuroendocrine tumours (NETs)
Title: Radiopharmaceutical Production of [61Cu]Cu-NODAGA-LM3 Injection Solution
Session: Efficient Radiolabelling: Key for Clinical Translation
Presenter: Manuel Alejandre-Lafont, PhD, Head QC/QA Radiopharmaceutical Chemistry at University Hospital Basel
Date & Time: September 11th, 4:45 pm CEST
Summary:
The presentation will highlight NUCLIDIUM’s 61Cu production process, which was developed together with the University Hospital Zurich, and the labelling method and clinical transfer for the TraceNETTM lead diagnostic candidate, which was developed at the University Hospital Basel. TraceNETTM is designed to improve the visualization of somatostatin-receptor-expressing neuroendocrine tumours (NETs). The established technology allows to produce 61Cu in high yields and purity in a cyclotron and efficient labelling of the tumour-targeting molecule. Due to its favourable half-life properties, 61Cu enables a wide distribution radius, potentially broadening the patient population that can get access to 61Cu-based radiodiagnostics. The successfully established process enables clinical-scale production of the diagnostic candidate.
Poster presentation on the development and selection of the lead diagnostic candidate from the NuriProTM prostate cancer program
Title: 61Cu-PSMA PET in prostate cancer: development and selection of the first radioligand for clinical translation
Session: New Imaging Agents
Presenter: Prof. Melpomeni Fani, PhD, Division Head Radiopharmaceutical Chemistry at University Hospital Basel
Date & Time: September 13th, 9:45 am CEST
Summary:
The poster presentation will describe the development and lead candidate selection of the NuriProTM program’s 61Cu-based diagnostic to improve the visualization of prostate cancer. Two newly developed 61Cu-based diagnostic conjugates targeting Prostate-Specific Membrane Antigen (PSMA) with either DOTAGA or NODAGA as the chelator were compared preclinically against two currently used standard prostate cancer diagnostics based on 68Ga and 18F, respectively. In these, the NODAGA-conjugated NuriProTM diagnostic candidate exhibited superior biodistribution and pharmacokinetics than the DOTAGA-conjugate. In comparison to the standard diagnostics, the NODAGA-conjugated candidate showed a similar biodistribution but better results for delayed imaging due to improved tumour-to-background ratio in the imaging scan. Based on these findings, the NODAGA-conjugated variant was selected as the lead diagnostic candidate for translation into clinical trials.